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The  aims  of  the  current  study  were  to  prepare  chitosan  nanoparticles  (CNPs)  and  to evaluate
its  protective  role alone  or in combination  with  quercetin  (Q)  against  AFB1-induce  cytotox-
icity  in  rats.  Male  Sprague-Dawley  rats  were  divided  into  12  groups  and  treated  orally  for
4 weeks  as  follow:  the control  group,  the  group  treated  with  AFB1 (80  g/kg b.w.)  in  corn
oil,  the groups  treated  with  low  (140  mg/kg  b.w.)  or  high  (280  mg/kg  b.w.)  dose  of  CNPs,  the
group  treated  with  Q (50  mg/kg  b.w.),  the  groups  treated  with Q  plus  the  low  or the  high
dose  of CNPs  and  the groups  treated  with  AFB1 plus  Q and/or  CNPs  at the two  tested  doses.
The  results  also  revealed  that  administration  of AFB1 resulted  in  a signiﬁcant  increase  in
serum  cytokines,  Procollagen  III, Nitric  Oxide,  lipid  peroxidation  and DNA  fragmentation
accompanied  with  a signiﬁcant  decrease  in GPx  I and  Cu–Zn  SOD-mRNA  gene  expression.  Qiver
ene expression
and/or CNPs  at  the  two  tested  doses  overcome  these  effects  especially  in  the  group  treated
with the high  dose  of  CNPs  plus  Q. It could  be  concluded  that  CNPs  is  a promise  candidate
as  drug  delivery  enhances  the  protective  effect  of Q  against  the cytogenetic  effects  of AFB1
in high  endemic  areas.
©  2015  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under
Y-NC-Nthe  CC  B
. Introduction
Aﬂatoxin B1 (AFB1) is mainly synthesized by Aspergillus
avus and Aspergillus parasiticus,  and is commonly found
s a contaminant in cereals and oilseeds. It is one of
he most relevant mycotoxins worldwide due to its
∗ Corresponding author. Tel.: +20 2 2283 1943; fax: +20 2 3337 0931.
E-mail address: mosaad abdelwahhab@yahoo.com
M.A. Abdel-Wahhab).
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214-7500/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open ac
icenses/by-nc-nd/4.0/).D  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
widespread occurrence, high toxicity and economic impli-
cations [1]. The exposure to AFB1 resulted in growth
stunting, immunosuppression, mutagenicity, genotoxicity,
increasing hepatocellular carcinoma (HCC) incidence in
animals and humans [2–4]. The genotoxic and carcinogenic
effects of AFB1 are intimately linked with its biotransforma-
tion through the cytochrome P450 to the highly reactive
AFB1-exo-8,9-epoxide, which can form adducts with the
DNA [5] and produce reactive oxygen species (ROS)
[6,7]. Moreover, AFB1 carcinogenicity has been associated
with altered expression of many p53-target genes and
cess article under the CC BY-NC-ND license (http://creativecommons.org/
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induction of mutations, principally the p53 codon 249
hotspot mutation [8].
Hepatic diseases represent a serious health problem all
over the world and the modern medicine as well as the
traditional herbal formulations offers few effective treat-
ments [9]. Numerous medicinal plant formulations are
used to treat liver disorders in traditional therapy. Most
of these treatments act as radical scavengers, whereas
others are enzyme inhibitors or mitogens [10]. Quercetin
(Q) is a major ﬂavonoid widely found in natural plants
and has become an essential part of the human diet. It
has been attested that the average daily intake of Q in
the diet of the Netherlands is 23 mg  [11]. Recently, Q
has drawn attention for its remarkable scope of health
beneﬁts, which make it a leading compound for devel-
oping new and effective functional foods or medicines
[11,12]. It is well documented that Q has broad bioac-
tivity, such as anti-proliferative and anticancer properties
[13,14], anti-ﬁbrotic [15,16], anti-coagulative [17], anti-
bacterial [18], anti-atherogenic [19,20], anti-hypertensive
[21,22] and anti-inﬂammatory capacities [23–26]. Several
studies have reported that Q possessing an excellent efﬁ-
cacy of scavenging free radicals [27], which is stronger than
the traditional antioxidants Vitamin C and Vitamin E [28].
However, the solubility of Q is poor due to its chemical
structure which is known to have low bioavailability, and
only a small percentage of ingested Q is absorbed into circu-
lation [12]. Therefore, various attempts have been made to
improve the bioavailability of Q via chemical modiﬁcation
[29].
Chitosan (CS) is an amino polysaccharide derived from
deacetylation of chitin of arthropods and insects exoskele-
ton and considered a dietary ﬁber due to indigestibility by
digestive enzymes [30]. CS has many functions in the ﬁelds
of biomedicinal and pharmaceutical products, food preser-
vation and microbial mitigation [31]. These biological
activities include immunopotentiating, antitumor, antihy-
pertensive, and antimicrobial actions [32,33], antioxidant
properties and free radical scavenging activity [34–36]. CS
was reported to affect the mitogenic response as well as the
chemotactic activities of animal cells [37] and is believed
to treat obesity in humans [38] and reduces both body
weight and cholesterol in animals and humans [39,40].
However, because of its high molecular weight and water-
insolubility, the applications of CS are severely limited. As
a solution, nanoparticle formulation provides a plausible
pharmaceutical basis for enhancing oral bioavailability and
therapeutic efﬁcacy of CS and other drugs that are poorly
soluble [41]. Chitosan nanoparticles (CNPs) exhibit more
superior activities than CS and have been reported to have
heightened immune-enhancing effect, anticancer activity
and antimicrobial activity than those of CS. In addition,
nanoparticles possess a stronger curvature of the surface,
compared to large particles [42]. The increased saturation
solubility, in turn, favors an increase in concentration gra-
dient between intestinal epithelial cells and the mesenteric
circulation beneath. The aims of the present study were to
prepare and characterize CNPs and to evaluate the pos-
sible hepatoprotective activity of CNPs and Q singly or
in combination against AFB1-induced oxidative stress and
cytotoxicity in rat liver.y Reports 2 (2015) 737–747
2. Materials and methods
2.1. Chemical and kits
Chitosan (high molecular weight, Mw 165–175 kDa)
was  purchased from Sigma–Aldrich (Paris, France). Aﬂa-
toxin B1 (AFB1) standards, quercetin extract, Sodium
tripolyphosphate (TPP) AND RevertAidTM H Minus First
Strand cDNA Synthesis Kit were purchased from Sigma
Chemical Co. (St. Louis, MO,  USA). Interleukin-1  (IL-1 ),
Procollagen III and Tumor Necrosis Factor-alpha (TNF-)
kits were purchased from Orgenium (Helsinki, Finland).
Glutathione peroxidase (GPx) and Superoxide dismutase
(SOD), lipid peroxidation (MDA), nitric oxide (NO) and car-
cinoembrionic antigen (CEA) kits were purchased from
Biodiagnostic Co. (Giza, Egypt). TRIZOL reagent was pur-
chased from InvitrogenTM (Carlsbad, CA, USA). All other
chemicals used throughout the experiments were of the
highest analytical grade available.
2.2. Preparation and characterization of chitosan
nanoparticles (CNPs)
Twenty mg  CS was  dissolved in 40 ml  of 2.0% (v/v)
acetic acid. A 20 ml  of 0.75 mg/ml  sodium tripolyphosphate
was  dropped slowly with stirring. Supernatant was  dis-
carded and CNPs were collected and air dried for further
use and analysis [43]. The size of CNPs was determined
using Nanotrac analyzer 6Hx4Wx15D, Model – Nanotrac
150 (Betatek Inc., Toronto, ON, Canada) with a measuring
range of 0.8–6500 nm (10–9 m).  CNPs were cut into pieces
of various sizes and wiped with a thin gold–palladium layer
by a sputter coater unit (UG-microtech, UCK ﬁeld, UK). FTIR
spectra of CS and CNPs were determined using an infrared
spectrometer (FTIR) (Thermo Fisher Scientiﬁc Inc., Nico-let
iS10, USA). Powdered CNPs were obtained by freeze-drying
and the samples were prepared using KBr to form pellets.
Using UV–vis spectrophotometric method, UV–vis spectra
of electrolyte solution of CS and CNPs were obtained using a
perkin-Elmer UV–Vis Lambda 35 spectrophotometer scan-
ning 200–800 nm.  All measurements were carried out at
least in triplicate.
2.3. Animals and experimental design
Three-month old male Sprague-Dawley rats (100–150 g
each) were purchased from Animal House Colony, National
Research Center, Dokki, Giza, Egypt. Animals were main-
tained on standard lab diet (protein: 160.4; fat: 36.3; ﬁber:
41 g/kg, namely 12.1 MJ  of metabolized energy) purchased
from Meladco Feed Co. (Aubor City, Cairo, Egypt) and
housed in ﬁlter-top polycarbonate cages in a room free
from any source of chemical contamination, artiﬁcially illu-
minated (12 h dark/light cycle) and thermally controlled
(25 ± 1 ◦C) at the Animal House Lab., National Research
Center, Dokki, Cairo, Egypt. All animals were received
humane care in compliance with the guidelines of the Ani-
mal  Care and Use Committee of the National Research
Center, Dokki, Giza, Egypt and the National Academy of
Sciences and published by the National Institutes of Health
(NIH publication 86-23 revised 1985).
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Animals were divided into twelve groups (10 rats/
roup) and were maintained on their respective diet for 4
eeks as follow: group 1, normal control animals; Group 2,
nimals treated orally with AFB1 (80 g/kg b.w.) suspended
n corn oil; Groups 3 and 4, animals treated daily with low
140 mg/kg b.w.) and high (280 mg/kg b.w.) dose of CNPs
CNPs-LD, CNPs-HD); Group 5, animals treated daily with
 (50 mg/kg b.w.); Groups 6 and 7, animals treated orally
ith Q plus CNPs-LD or CNPs-HD respectively; Groups 8
nd 9, animals treated orally with AFB1 plus CNPs-LD and
NPs-HD respectively; Group 10, animals treated orally
ith AFB1 plus Q; Groups 11 and 12, animals treated orally
FB1 plus Q and CNPs-LD or CNPs-HD respectively. The ani-
als were observed daily for signs of toxicity during the
xperimental period. At the end of the treatment period (i.e.
ay 28), all animals were fasted for 12 h, then blood sam-
les were collected from the retro-orbital venous plexus
nder diethyl ether anesthesia. Sera were separated using
ooling centrifugation and stored at −20 ◦C until analy-
is. The sera were used for the determination of IL-,
rocollagen III, NO, TNF- and CEA according to the kits
nstructions.
After the collections of blood samples, animals were
acriﬁced and samples of the liver of each animal were
issected, weighed and homogenized in phosphate buffer
pH 7.4) to give 20%, w/v, homogenate according to Lin
t al. [44]. This homogenate was centrifuged at 1700 rpm at
◦C for 10 min; the supernatant was stored at −70 ◦C until
nalysis. This supernatant (20%) was used for the deter-
ination of hepatic lipid peroxidation (MDA) and it was
urther diluted with phosphate buffer solution to give 2
nd 0.5% dilutions for the determination of hepatic GPx
2%) and SOD (0.5%) activities according to the kits instruc-
ions. Other samples of liver each animal were dissected for
olecular analyses.
.4. Molecular analyses
.4.1. Total RNA extraction
Frozen liver tissue samples (50–100 g) from each ani-
al  within different treatment groups were thawed and
omogenized in TRIZOL reagent. The solution of extracted
NA was recovered in 100 l molecular biology grade
ater. The total RNA samples were pretreated using
NA-freeTM DNase to remove any possible genomic DNA
ontamination according to manufacturer’s protocol. The
uality of the RNA was determined using spectropho-
ometer at 260 nm by UV visualization of an ethidium
romide-stained agarose-formalin gel.
.4.2. Reverse transcription
Single strand cDNA was synthesized for PCR and
emi-nested PCR purposes using total RNA isolated from
ifferent tissues and oligo(dT)18 as primer for reverse
ranscriptase. The reaction mixture of 20 l used in the 1st
tep of cDNA synthesis included 4 l of total RNA (2 g),
.5 l oligo(dT)18 (10 M),  and 5 l of DEPC-treated water.
he reaction mixture was incubated at 70 ◦C for 5 min. A
 l of 5X M-MuLV-Reverse Transcriptase buffers, 2 l of
0 mM dNTP mix, 0.5 l of dH2O and 0.5 l (20 units) of
ibonuclease inhibitor was added to the above reactiony Reports 2 (2015) 737–747 739
mixture. The above mixtures were further incubated at
37 ◦C for 5 min. 2 l (40 units) M-MuLV-Reverse Transcrip-
tase was  then added and cDNA was  synthesized for 60 min
at 42 ◦C. The reaction was  stopped by heating the reaction
mixture at 70 ◦C for 10 min. The cDNA thus synthesized was
stored at −20 ◦C.
2.4.3. Polymerase chain reaction (PCR)
The ﬁrst-strand cDNA from different rat samples was
used as the template for ampliﬁcation by the PCR with the
pairs of speciﬁc primers presented in Table 1 (from 5′ to 3′)
according to Limaye et al. [45]. -Actin, a house-keeping
gene was used for normalizing mRNA levels of the target
genes. The PCR cycling parameters were one cycle of 94 ◦C
for 5 min, 35 cycles of 94 ◦C for 30 s, 60 ◦C for 30 s, 70 ◦C for
40 s, and 72 ◦C for 5 min  for Cu–Zn SOD using hydrogen
peroxidae and for GPx I gene using horseradish peroxi-
dase substrate according to the instructions supplied by
the producer company. The PCR product was run on a 1.5%
agarose gel in Tris-borate-EDTA buffer and visualized over
a UV Trans-illuminator. The ethidium bromide-stained
gel bands were scanned and the signal intensities were
quantiﬁed by the computerized Gel-Pro (version 3.1 for
window 3). The ratio between the levels of the target
gene ampliﬁcation product and the -actin (internal con-
trol) was  calculated to normalize for initial variation in
the sample concentration as a control for reaction efﬁ-
ciency [46]. All PCRs were independently replicated three
times.
2.5. Quantiﬁcation of DNA fragmentation
DNA fragmentation in liver tissue was carried out
according to Wu et al. [47] with some modiﬁcation. Brieﬂy,
about 50 mg  of liver tissue were homogenized in lysis
buffer pH 8.0 (10 mM Tris base, 1 mM EDTA and 0.2% triton
X-100) and incubated on ice for 20 min. The cell lysate were
centrifuged at 12,000 rpm for 30 min  at 4 ◦C. The super-
natant containing small DNA fragments was separated.
The supernatant and pellet were re-suspended in 1 N and
0.5 N of perchloric acid respectively. Then samples were
heated at 90 ◦C for 20 min  and centrifuged at 11,000 rpm
for 10 min  to remove proteins. Supernatant fractions were
reacted with diphenylamine (DPA) for 16–20 hr at room
temperature and the developing blue color was measured
at 600 nm using a UV-double beam spectrophotometer
(Shimadzu 160 A; Shimadzu Corporation, Kyoto, Japan).
DNA fragmentation in samples was  calculated as follow:
[(fragmented DNA in supernatant)/fragmented DNA  in
supernatant + intact DNA in pellet) × 100]. The data were
expressed as percentage of total DNA appearing in the
supernatant fraction.
2.6. Statistical analysis
The experimental results were expressed as the
mean ± SEM with ten rats in each group. The intergroup
variation between various groups were analyzed sta-
tistically using one-way analysis of variance (ANOVA)
followed by Duncan’s multiple range test [48] using statis-
tics software package SPSS for Windows, V. 13.0 (Chicago,
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Table  1
Details giving primer sequences and expected product sizes for the genes ampliﬁed.
cDNA Genbank accession no. Forward primer Reverse primer RT-PCR product size
-Actin V01217 5′-CTGCTTGCTGATCCACA 5′-CTGACCGAGCGTGGCTAC 505 bp
′ GGTGA ′
ACAGT
xidase.
to diminish the liver genomic DNA fragmentation whichCu–Zn  SOD X05634 5 -GCAGAAGGCAAGC
GPx  I M21210 5′-CTCTCCGCGGTGGC
Cu–Zn SOD – copper zinc superoxide dismutase; GPx I – glutathione pero
USA). P values ≤0.05 were considered as statistically
signiﬁcant.
3. Results
3.1. Characterization of CNPs
The size measurements of CNPs revealed that the aver-
age particles size was around 100 nm and size distribution
was in the range of 100–600 nm (Fig. 1A). The FT-IR spec-
tra of the CS and CNPs showed a new peak for CNPs appear
at 1256 cm−1 indicating P O stretching and the intensity
of NH2 band appear at 1628 cm−1, which can be observed
clearly in CS and decreased dramatically since a new sorp-
tion band at 1550 cm−1 was appeared (Fig. 1B). The UV–vis
spectra of CS and CNPs are shown in Fig. 1C and D and
revealed signiﬁcant changes in the UV/vis spectra of CNPs
were observed compared to CS. Moreover, a large increase
of the absorbance in the range of 250–350 and 350–450 nm
was observed in the spectra of CNPs.
3.2. Biochemical and molecular analyses
The results of the current study revealed that treatment
with AFB1 resulted in a signiﬁcant increase in CEA, TNF-
, IL-1, Procollagen III and NO (Table 2). Treatment with
CNPs-LD or CNPs-HD showed a signiﬁcant decrease in CEA
and NO but did not signiﬁcantly affect TNF-, IL-1 and
Procollagen III. Treatment with Q alone resulted in a sig-
niﬁcant decrease in CEA however the other parameters
were in the normal range of the control. Animals treated
with Q plus CNPs-LD or CNPs-HD showed insigniﬁcant
changes in TNF-, IL-1, Procollagen III and NO although
it decreased signiﬁcantly CEA. This decrease was more
pronounced in the group treated with Q plus CNPs-HD.
Treatment with AFB1 plus Q or CNPs at the two  tested
doses resulted in a signiﬁcant improvement in all the tested
parameters toward the control values and CNPs-HD suc-
ceeded to normalize CEA and TNF-. On the other hand,
animals treated with AFB1 plus Q and CNPs-LD showed
a signiﬁcant decrease in CEA level TNF-, IL-1, Procolla-
gen III and NO compared to AFB1 alone-treated group and
this treatment succeeded to normalize CEA. However, the
group treated with AFB1 plus Q and CNPs-HD was com-
parable to the control group in all the parameters tested
(Table 2).
The results of the current study revealed that treatment
with AFB1 resulted in a signiﬁcant decrease in hepatic GPx
and SOD (Fig. 2) accompanied with a signiﬁcant increase
in MDA  (Fig. 3). Treatment with Q, CNPs-LD or CNPs-HD
resulted in a signiﬁcant increase in GPx and SOD accom-
panied with a signiﬁcant decrease in MDA  level only inAC 5 -TAGCAGGACAGCAGATGAGT 387 bp
 5′-CCACCACCGGGTCGGACATAC 290 bp
the groups treated with CNPs-HD or Q. The combined
treatment with Q and CNPs-LD or CNPs-HD resulted in
a signiﬁcant increase in the antioxidant enzymes accom-
panied with a signiﬁcant decrease in MDA  which was
more pronounced in the group received Q plus CNPs-HD.
The combined treatment with AFB1 plus Q and/or CNPs
at the two tested doses succeeded to induce a signiﬁcant
improvement in the antioxidant enzymes and lipid peroxi-
dation toward the control levels. Moreover, in AFB1-treated
groups, Q plus CNPs-LD succeeded to normalize MDA  and
Q plus CNPs-HD could increase GPx and SOD above the
normal level of the control group.
The cytogenetic results revealed that the liver genes
were seriously affected with AFB1 treatment while upon
treatment with CNPs whether in low or high dose, a sig-
niﬁcant improvement was achieved. The ratio of optical
density indicated that the expressions of GPx mRNA (Fig. 4)
and Cu–Zn SOD mRNA (Fig. 5) were signiﬁcantly decreased
in AFB1-treated animals compared to the control group.
Treatment with CNPs-LD or CNPs-HD resulted in a sig-
niﬁcant increase in GPx mRNA and Cu–Zn SOD mRNA
expression however; animals treated with Q alone were
comparable to the control group. The combined treatment
with Q and/or CNPs resulted in a signiﬁcant increase in
GPx mRNA and Cu–Zn SOD mRNA expression which was
more pronounced in the group received Q plus CNPs-HD.
Administration of AFB1 plus Q alone or in combination with
CNPs-LD or CNPs-HD resulted in a signiﬁcant improvement
in GPx mRNA and Cu–Zn SOD mRNA expression toward
the control level (Figs. 4 and 5 respectively). This improve-
ment was pronounced in the group treated with Q plus
CNPs-LD and more pronounced in the group received Q plus
CNPs-HD.
3.3. DNA fragmentation assay
The effect of different treatments on DNA damage
revealed that treatment with AFB1 alone caused a sig-
niﬁcant increase in the percentage of liver genomic DNA
fragmentation (Table 3) which reached 41.35% compared
with the control group (6.09%). However, there was  no sig-
niﬁcant change in liver genomic DNA fragmentation in the
groups treated with Q and/or CNPs at the two  tested doses.
The administration of CNPs-LD or CNPs-HD plus AFB1 suc-
ceeded in blunting liver genomic DNA fragmentation which
decreased to 24.8, 14.8% in the low and high doses respec-
tively. However, administration of Q plus AFB1 succeededreached 27.4%. On the other hand, treatment with CNPs-
LD or CNPs-HD plus Q showed a further decrease in the
percentage of DNA fragmentation to reach 20.2 and 11.6%,
respectively.
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. Discussion
The results of FT-IR reported in the current study
howed that anionic phosphate groups of sodium
olyphosphate were interacted with the cationic amino
roups of CS similar to that described in previous reports
49,50]. This interaction enhanced both the inter and
ntramolecular interaction of CNPs. Moreover, the results
f UV–vis spectra conﬁrmed the formation of a complex
etween sodium tripolyphosphate and CS. According to
ahima et al. [51], the range 250–350 nm is correspond-
ng to the electronic transition involving the lone pair of
lectrons on the sodium tripolyphosphate oxygen atom
able 2
ffect of oral administration of AFB1 alone or in combination with Q and/or CNPs
Parameter groups CEA (ng/ml) TNF- (ng/l) 
Control 2.75 ± 0.34a 57.3 ± 2.95 a
AFB1 9.54 ± 1.51b 96.42 ± 2.33b
CNPs-LD 2.55 ± 0.62a 55.23 ± 2.63a
CNPs-HD 2.66 ± 0.52a 56.72 ± 2.47a
Q 2.71 ± 0.33a 57.22 ± 2.62a
CNPs-LD + Q 2.77 ± 0.37a 56.92 ± 1.94a
CNPs-HD + Q 2.79 ± 0.64a 58.1 ± 3.42a
CNPs-LD + AFB1 4.93 ± 0.86c 67.53 ± 3.63c
CNPs-HD + AFB1 4.22 ± 0.77c 62.75 ± 2.96d
Q + AFB1 4.76 ± 1.22c 64.83 ± 2.67e
CNPs-LD + Q + AFB1 3.95 ± 0.93d 60.42 ± 1.69d
CNPs-HD + Q + AFB1 2.83 ± 0.92a 58.52 ± 2.66a
ithin each column, means superscript with different letters are signiﬁcantly difs, (B) FT-IR spectra of (a) chitosan and (b) chitosan nano particles (CNPs),
and/or phosphate group. Moreover, the appearance of a
broad band around 350–450 nm can be explained by the
formation of the complex between the oxygen and/or phos-
phate groups and ammonium groups of CS. These ﬁndings
give a strong evidence of the possibility of the interaction
between anionic phosphate groups of sodium polyphos-
phate and the cationic amino groups of CS.
The in vivo results of the current study revealed that
treatment with AFB1 resulted in a signiﬁcant increase in
CEA, TNF-, IL-1 , Procollagen and NO in serum. Therefore,
the current study afﬁrmed that AFB1 can induce hepato-
toxicity in rats via the elevation of CEA level in serum as
was suggested earlier [52–54]. It is well documented that
 on serum cytokines, procollagen III and nitric oxide.
IL-1 (ng/ml) Procollagen III (g/l) NO (mol/l)
0.75 ± 0.03a 2.6 ± 0.12a 34.74 ± 1.93a
4.24 ± 0.93b 8.96 ± 0.86b 85.83 ± 2.44b
0.74 ± 0.02a 2.55 ± 0.21a 33.86 ± 2.45a
0.77 ± 0.04a 2.59 ± 0.23a 34.62 ± 2.09a
0.76 ± 0.04a 2.89 ± 0.31a 35.64 ± 1.88a
0.77 ± 0.05a 2.49 ± 0.47a 35.43 ± 2.53a
0.77 ± 0.07a 2.58 ± 0.41a 35.82 ± 2.94a
2.99 ± 0.75c 5.74 ± 1.22d 57.83 ± 2.44c
2.53 ± 0.84c 4.96 ± 1.31d 55.83 ± 2.48c
2.67 ± 0.45c 4.99 ± 1.08d 59.84 ± 2.45c
1.87 ± 0.54e 3.83 ± 0.89e 43.82 ± 2.94d
1.22 ± 0.23e 2.83 ± 0.77a 38.32 ± 2.76e
ferent (P ≤ 0.05).
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column,  means superscript with different letters are signiﬁcantly differen
TNF-, IL-1 and NO are produced by macrophages and
they play a vital role in tumor conditions [54–56] and TNF-
 is an essential factor in tumor promotion [57]. Moreover,
TNF- is a key factor that regulates the production of other
Table 3
Effects of AFB1 administration alone or plus Q and/or CNPs on the per-
centage of DNA fragmentation in liver of rats.
Groups DNA fragmentation (%) % of changes
Control 6.09a 0
AFB1 41.35b +35.26
CNPs-LD 5.7a −0.39
CNPs-HD 5.4a −0.69
Q 6.0a −0.09
CNPs-LD + Q 5.2a −0.89
CNPs-HD + Q 5.0a −1.09
CNPs-LD + AFB1 24.8c +18.71
CNPs-HD + AFB1 14.8d +8.71
Q  + AFB1 27.4e +21.31
CNPs-LD + Q + AFB1 20.2f +14.11
CNPs-HD + Q + AFB1 11.6g +5.51
Percentages values superscript with different letters are signiﬁcantly dif-
ferent (P ≤ 0.05).on hepatic MDA  content. Data are expressed as mean ± SEM. Within each
05)
cytokines involved in chronic inﬂammation and tumor
development, through the NF-kB pathway [58]. The role of
NO in cell death is complex and the increased level of NO
reported herein suggested that AFB1 preferentially affect
macrophage functions [53,59–61]. Moreover, the genera-
tion of NO by the inducible nitric oxide synthase (iNOS)
plays a key role in the cytokine-mediated cell destruction
[62]. On the other hand, the increased level of Procolla-
gen III reported in the current study in AFB1-treated rats
indicated the impact of this mycotoxin on liver damage as
suggested by Leonardi et al. [63] who reported that procol-
lagen III is signiﬁcantly high in patients with chronic HCV
with either normal or high transaminase activity. Gener-
ally, ingestion of AFB1 signiﬁcantly increased TNF-, NO
and IL-1 through its effects on macrophage functions [64]
and conﬁrmed the results of Barton et al. [65] who  stated
that TNF- plays a causal role in the development of liver
injury.The decrease in GPx and SOD and the increase in MDA
level in the liver of AFB1-treated rats might indirectly lead
to an increase in oxidative DNA damage [53,66,67]. Pre-
vious studies on the mechanisms of AFB1-induced liver
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njury have demonstrated that glutathione and SOD play
n important role in the detoxiﬁcation of the reactive and
oxic metabolites of this mycotoxin, and that the liver
ecrosis begins when the glutathione stores are almost
xhausted [6,54,68–71]. Moreover, AFB1-epoxide, the toxic
etabolite of AFB1, is converted into AFB1-GSH catalyzed
y the cellular glutathione-S-transferase and the level
f this enzyme is critical to modulate AFB1 metabolism
72]. The decrease in GPx and SOD was further conﬁrmed
y the decrease in GPx I mRNA and Cu–Zn SOD mRNA
xpression in AFB1-treated animals compared to the con-
rol group. This decrease in GPx, and Cu–Zn SOD mRNA
xpression in the liver tissue was accordance with the
revious reports [73–76] and could be either due to the
xidation of transcription factors or due to the decrease
ig. 5. The ratio between Cu–Zn SOD/-actin mRNA in rat treated with AFB1
ean  ± SEM for each group. Column superscripts with different letter are signiﬁcn combination with Q and/or CNPs. Values are expressed as mean ± SEM
t (P ≤ 0.05).
in the half lives of mRNAs [77]. Consequently, under
this pathological condition, the active process of cellular
self-destruction, DNA fragmentation and apoptosis, might
occur [69,78].
Lipid peroxidation (LP) is one of the main manifes-
tations of oxidative damage and it plays an important
role in the toxicity and carcinogenicity [71,79]. Accord-
ing to Choi et al. [80], AFB1-mediated toxicity was found
to be related to its pro-oxidant potential. This is because
the generation of reactive oxygen species (ROS) includ-
ing superoxide anion (O2−), hydrogen peroxide (H2O2),
−and hydroxyl radical ( OH) during the metabolic process
of AFB1 by liver enzymes [81]. The signiﬁcant increase
observed in hepatic MDA  levels in the group received
AFB1 alone may  be attributed to the generation of a high
alone or in combination with Q and/or CNPs. Values are expressed as
antly different (P ≤ 0.05).
oxicolog
effects were more pronounced in the animals treated with744 M.A. Abdel-Wahhab et al. / T
level of free radicals, which could not be tolerated by the
cellular antioxidant defense system. LP can be classiﬁed
as free radical-mediated and non-free radical-mediated LP
[82]. Free radical-mediated LP involves a series of reac-
tions, which result in the oxidation of the lipid molecules of
free radicals [83]. However, most cells tolerate mild LP by
means of their antioxidant defense system [84]. The effects
of free radicals on lipids, DNA and proteins are controlled by
antioxidant enzymes, namely, SOD, CAT and GPx, as well as
by nonenzymatic antioxidants, including the vitamins A, E,
C, and glutathione [66,76,85,86]. Oxidative damage to cells
and tissues occurs if the reactive oxygen species exceeding
the antioxidant capacity of the cell and the primary deter-
minants of the cellular antioxidant defense system are the
intermediate and end-products of LP and enzymatic and
non-enzymatic antioxidants [53,75,87].
The increase in DNA fragmentation reported in the
current study was consistent with the previous reports
which indicated that AFB1 induce DNA fragmentation
[69,76,78,88]. The mutagenicity of AFB1 arising from the
toxin molecules which might be forming covalent-adducts
resulting in disturb of DNA replication [89]. The formation
of AFB1-DNA adducts is regarded as a critical step in the ini-
tiation of AFB1-induced hepatocarcinogenesis [54,90,91]
and p53 gene mutation [92] indicated that oxidative stress
is an apoptosis inducer [93].
The current results revealed that administration of
both Q and/or CNPs at the two tested doses succeeded to
induce a signiﬁcant improvement in all the tested param-
eters including the cytokines, procollagen III, antioxidant
enzymes, gene expression, oxidative stress markers (MDA
and NO) and DNA fragmentation. These ﬁndings are in har-
mony with the previous reports who suggested a protective
role of CNPs with a mean diameter of 83.66 nm against
H2O2-induced RAW-264.7 cell injury through restoring
the activities of endogenous antioxidants (SOD, GPx and
CAT), along with enhancement of their gene expression
[94]. Although no available report describe the protec-
tive role of CNPs against AFB1-induced hepatotoxicity
and oxidative stress in liver tissues, the hepatoprotective
effect of CS has been documented in several reports. Jeon
et al. [95] investigated the antioxidative effect of CS on
chronic CCl4-induced hepatic injury in rats and showed
that CS has strong antioxidative effects, which decrease
TBARS production and increase antioxidant enzyme (cata-
lase and SOD) activities. Moreover, Subhapradha et al.
[96] reported that -Chitosan from Gladius of Sepio-
teuthis lessoniana has a hepatoprotective effect against
CCl4-induced oxidative stress in rats. These authors con-
cluded that in addition to normalizing the oxidative stress
markers, -Chitosan succeeded to normalize plasma AST
and ALT levels in CCl4-treated rats which indicate that
-chitosan may  stabilize the cell membrane and may  pre-
vent a leakage of intracellular enzymes into the blood.
Consequently, the overall hepatoprotective effect of CS
is probably due to a counteraction of free radicals by its
antioxidant nature and/or to its ability to inhibit lipid
accumulation by its antilipidemic property [97,98]. In this
concern, Santhosh et al. [99] showed that co-treatment
with CS may  prevent antitubercular drugs-induced hepa-
totoxicity in rats. Moreover, CS was also effective againsty Reports 2 (2015) 737–747
TCDD-induced hepatotoxicity [100] and was  proved to
protect liver against oxidative damage induced by radio-
therapy [101].
On the other hand, the hepatoprotective and antioxi-
dant properties of Q are suggested by Pavanato et al. [102]
who  found that Q signiﬁcantly improved all the hepatic
toxicity biomarkers in CCl4-induced liver ﬁbrosis in addi-
tion to improve liver histology of rats. Moreover, Q was
found to modify LPS-induced hepatotoxicity and oxida-
tive stress and protected rat liver against chemicals- or
drugs-induced hepatotoxicity [103]. Furthermore, Utesch
et al. [104] demonstrated that oral administration of Q did
not induce any genotoxic effects in vivo. The hepatopro-
tective effect of Q was also investigated by Padma et al.
[105] who concluded a protective effect against oxida-
tive damage due to its free radical scavenging action and
antioxidant nature. In the same respect, Abo-Salem et al.
[106] showed that treatment with Q decreased the ele-
vation in biochemical parameters induced by acrylonitrile
and it was effective in structural improvement of liver.
Another study demonstrated that administration of Q prior
to sodium ﬂuoride intoxication prevents hepatotoxicity
and oxidative stress in rat liver, probably due to its antiox-
idant effect [107]. Recently, Tang et al. [108] reported that
Q suppressed CYP2E1-dependent ethanol hepatotoxicity.
The current results afﬁrmed that, beside the protective role
of CNPs alone, it enhanced the antioxidant effect of Q and
overcome the problem associated with its poor absorption
and bioavailability upon oral administration. In a recent
study, Torresa et al. [109] synthesized chitosan-ﬂavonoid
conjugate by covalent enzymatic CS modiﬁcation with Q
to enhance the antioxidant and antimicrobial properties
and retained thermal degradability. Taken together, the
current study indicated that both CNPs and Q alone or
in combination succeeded to induce a protective effect
against AFB1-induce liver toxicity and carcinogenicity via
up-regulating the expression of the antioxidant enzymes.
Furthermore, the decrease in DNA fragmentation in the
groups treated with CNPs and/or Q suggested that the pro-
tective effect of these agents during aﬂatoxicosis may  be
resulted from the reduction of apoptosis via the increase in
the expression of antioxidants enzymes as well as the free
radicals scavenging properties.
5. Conclusion
It could be concluded that exposure to AFB1 resulted
in severe oxidative stress and cytotoxicity in the liver typ-
ical to that reported in the literature. Co-treatment with
Q and/or CNPs at the two  tested doses succeeded to mit-
igation these toxic effects through several mechanisms
included the free radical scavenging properties, enhance-
ment of antioxidant capacity, reduction of inﬂammatory
cytokines and modulation of antioxidant gene expression
as well as the protection against DNA fragmentation. Thesethe high dose of CNPs plus Q. Consequently, CNPs is a safe
and consider a promise candidate for enhancing the role
of Q to counteract the health hazards of aﬂatoxin in the
endemic regions.
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